Hanmi Pharm secures up to $2.3 billion exclusive license with Genentech for novel obesity therapy HM17321
Executive summary: Hanmi Pharm announced an exclusive licensing agreement with Genentech for its obesity therapy candidate HM17321, a urocortin‑2 analog, with total potential value of up to $2.3 billion including upfront, milestone and royalty payments. The deal represents one of the largest recent partnerships in the obesity therapeutics space, underscoring strong commercial interest in next‑generation weight‑loss treatments and providing Hanmi with substantial funding to advance development.
Who is involved: Hanmi Pharm (South Korea), Genentech (a Roche subsidiary, United States), and the obesity therapy asset HM17321.
Likely next: Further preclinical and clinical development of HM17321 will proceed under Genentech’s oversight, with milestone payments triggered by predefined development and regulatory achievements.
Hanmi Pharm has entered an exclusive licensing agreement with Genentech to develop and commercialize HM17321, a proprietary urocortin‑2 analog aimed at chronic weight management. The agreement includes upfront payments, milestone payments and tiered royalties, with a total potential value of $2.3 billion. This partnership highlights continued investor and corporate interest in novel obesity treatments amid a crowded market.
Timeline
- — Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy (PR Newswire)
Analysis — what this means
Sectors affected
- Obesity drug development
- Biopharmaceutical licensing
Sources
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy — PR Newswire
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy — PR Newswire